Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma

International Journal of Urology

Volumn 9, Issue 10, 2002, Pages 531-538

  Takahashi, Masayuki ^a   Oka, Natuo ^a   Naroda, Takushi ^a   Nishitani, Masa Aki ^a   Kanda, Kazuya ^a   Kanayama, Hiro Omi ^a   Kagawa, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Gelatin zymography; Matrix metalloprotease 2; Multivariate analysis; Renal cell carcinoma; Survival

Indexed keywords

GELATIN; GELATINASE A; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SAMPLING; ZYMOGRAPHY; CANCER INVASION; CHEMISTRY; FEMALE; IN VITRO STUDY; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036434760     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00516.x     Document Type: Article

References (37)

1. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284: 67-8.
2. Barsky SH, Siegal GP, Jannotta F, Liotta LA. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab. Invest. 1983;49: 140-7.
3. Liotta LA. Tumor invasion and metastases: Role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 1986;46: 1-7.
4. Nakajima M, Welch DR, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res. 1987;47: 4869-76.
5. Hamdy FC, Fadlon EJ, Cottam D et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 1994;69: 177-82.
6. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9: 289-303.
7. Okada Y, Morodomi T, Enghild JJ et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur. J. Biochem. 1990;194: 721-30.
8. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells.Nature 1994;370: 61-5.
9. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 1995; 55: 3263-6.
10. Mori M, Mimori K, Shiraishi T et al. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int. J. Cancer 1997;74: 316-21.
11. Davies B, Miles DW, Happerfield LC et al. Activity of type IV collagenases in benign and malignant breast disease. Br. J. Cancer 1993;67: 1126-31.
12. Yamagata S, Yoshii Y, Suh JG, Tanaka R, Shimizu S. Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissues. Cancer Lett. 1991;59: 51-5.
13. McDonnell S, Navre M, Coffey RJ Jr, Matrisian LM. Expression and localization of the matrix metallopro-teinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol. Carcinog. 1991;4: 527-33.
14. Miyake H, Hara I, Yoshimura K et al. Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res. 1996;56: 2440-5.
15. Price JT, Wilson HM, Haites NE. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur. J. Cancer 1996;32: 1977-82.
16. Walther MM, Kleiner DE, Lubensky IA et al. Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology 1997; 50: 295-301.
17. Miyake H, Hara I, Gohji K et al. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. Clin. Cancer Res. 1999; 5: 2824-9.
18. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH. Expression of metalloprotein-ase 2 and 9 and their inhibitors in renal cell carcinoma. J. Urol. 1998;160: 1914-8.
19. Kitagawa Y, Kunimi K, Uchibayashi T, Sato H, Namiki M. Expression of messenger RNAs for membrane-type 1 1999, 2, and 3 matrix metalloproteinases in human renal cell carcinomas. J Urol. 1999;162: 905-9.
20. World Health Organization (1988). WHO International Histological Classification of Tumours. In: Mostfi FK, Davis CJ (eds). Springer, Berlin.
21. International Union Against Cancer (1997). TNM Classification of Malignant Tumours, 5th edn. In: Sobin LH, Wittekind C (eds). John Wiley, New York.
22. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 1980;102: 196-202.
23. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6: 121-5.
24. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res. Treat. 1993;24: 209-18.
25. Davies B, Waxman J, Wasan H et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 1993; 53: 5365-9.
26. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: A review. Crit. Rev. Oral Biol. Med. 1993;4: 197-250.
27. Grigioni WF, D'Errico A, Fiorentino M et al. Gelatinase A (MMP-2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties. Diagn. Mol. Pathol. 1994;3: 163-9.
28. Grigioni WF, D'Errico A, Fortunato C et al. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod. Pathol. 1994;7: 220-5.
29. Sier CF, Kubben FJ, Ganesh S et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer 1996;74: 413-17.
30. Brown PD, Bloxidge RE, Anderson E, Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin. Exp. Metastasis 1993; 11: 183-9.
31. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J. Natl Cancer Inst. 1993;85: 574-8.
32. Nakamura H, Ueno H, Yamashita K et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 1999; 59: 467-73.
33. Nomura H, Fujimoto N, Seiki M, Mai M, Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer 1996;69: 9-16.
34. Ueno H, Nakamura H, Inoue M et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res. 1997;57: 2055-60.
35. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int. J. Cancer 1995; 64: 355-9.
36. Maldazys JD, deKernion JB. Prognostic factors in meta-static renal carcinoma. J. Urol. 1986;136: 376-9.
37. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988;61: 1639-51.